Rothschild Investment Corp IL increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,963 shares of the medical research company’s stock after purchasing an additional 3,083 shares during the quarter. Amgen accounts for approximately 1.6% of Rothschild Investment Corp IL’s holdings, making the stock its 8th biggest position. Rothschild Investment Corp IL’s holdings in Amgen were worth $13,926,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. BlackRock Inc. lifted its holdings in Amgen by 3.4% in the second quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after acquiring an additional 1,585,911 shares during the period. Morgan Stanley lifted its holdings in Amgen by 0.5% in the second quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after acquiring an additional 34,674 shares during the period. Nuveen Asset Management LLC lifted its holdings in Amgen by 1,334.9% in the second quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after acquiring an additional 4,598,329 shares during the period. Nordea Investment Management AB lifted its holdings in Amgen by 5.0% in the first quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock valued at $894,700,000 after acquiring an additional 225,485 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Amgen by 9.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after acquiring an additional 239,576 shares during the period. 76.24% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have commented on AMGN shares. Evercore ISI reissued a “hold” rating on shares of Amgen in a report on Sunday, August 11th. Royal Bank of Canada restated a “hold” rating on shares of Amgen in a research report on Monday, September 30th. Morgan Stanley dropped their price target on Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research report on Monday, July 15th. Cowen set a $231.00 price target on Amgen and gave the company a “buy” rating in a research report on Sunday, September 29th. Finally, Cantor Fitzgerald set a $230.00 price target on Amgen and gave the company a “hold” rating in a research report on Monday, September 30th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $217.41.
Amgen stock traded up $2.12 during midday trading on Friday, reaching $200.80. 2,367,190 shares of the company were exchanged, compared to its average volume of 2,465,687. The company has a market capitalization of $117.59 billion, a price-to-earnings ratio of 13.94, a P/E/G ratio of 2.55 and a beta of 1.11. The firm’s 50-day simple moving average is $199.57 and its 200-day simple moving average is $186.20. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $211.90. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping analysts’ consensus estimates of $3.58 by $0.39. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.83 EPS. On average, analysts forecast that Amgen, Inc. will post 14.31 EPS for the current fiscal year.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Recession
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.